Global Autologous Cell Therapy Market Growth (Status and Outlook) 2025-2031

According to this study, the global Autologous Cell Therapy market size will reach US$ 20960 million by 2031.

Autologous cell therapy refers to the injection or delivery of human tissue or cells to the same person to treat pathological conditions. For the same purpose, the stem cells are taken out of the patient, harvested, cultured, and transplanted again to the same person. The purpose of this method is to reduce the chance of rejecting treatment in the body. In addition, autologous cell therapy does not require immunosuppression.

United States market for Autologous Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Autologous Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Autologous Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Autologous Cell Therapy players cover BioTime, Pharmicell, BrainStorm Cell Therapeutics, Opexa Therapeutics, Vericel Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Autologous Cell Therapy Industry Forecast” looks at past sales and reviews total world Autologous Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Autologous Cell Therapy sales for 2025 through 2031. With Autologous Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Autologous Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Autologous Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Autologous Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Autologous Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autologous Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autologous Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Autologous Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Bone Marrow
Epidermis

Segmentation by Application:
Neurology
Orthopedics
Cancer
Wound Healing
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BioTime
Pharmicell
BrainStorm Cell Therapeutics
Opexa Therapeutics
Vericel Corporation
Regeneus

Please note: The report will take approximately 2 business days to prepare and deliver. Show more